Coya Therapeutics (COYA) Cash from Operations (2022 - 2026)
Coya Therapeutics (COYA) posted Cash from Operations of 6208530.0 for Q1 2026, down 516.46% sequentially from 1007127.0 in Q4 2025, and down 119.52% YoY from 31811714.53 in Q1 2025.
Coya Therapeutics (COYA) Cash from Operations (2022 - 2026) Analysis & Trends
Coya Therapeutics has reported Cash from Operations for 5 years, with the latest figure at 6208530.0 in Q1 2026.
- Quarterly Cash from Operations fell 119.52% year-over-year to 6208530.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 14119556.0 (up 7.49% YoY) and the FY2025 annual result came in at 10739301.0, down 4.38% from the prior year.
- Cash from Operations declined to 6208530.0 in Q1 2026 per COYA's latest filing, from 1007127.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 2145874.0 in Q1 2024 and troughed at 6208530.0 in Q1 2026.
- A 5-year average of 2686165.76 and a median of 2241080.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations jumped 155.54% in 2024, then slumped 231.8% in 2025.
- Over 5 years, Cash from Operations stood at 2223075.0 in 2022, then decreased by 0.81% to 2241080.0 in 2023, then fell by 7.53% to 2409767.0 in 2024, then surged by 58.21% to 1007127.0 in 2025, then sank by 516.46% to 6208530.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 6208530.0, 1007127.0, and 1130603.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - | -7.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.38 Mn |
| Jun 30, 2026 | -7.38 Mn |
| Mar 31, 2026 | -6.21 Mn |
| Mar 31, 2026 | -6.21 Mn |
| Dec 31, 2025 | -1.01 Mn |
| Dec 31, 2025 | -1.01 Mn |
| Sep 30, 2025 | -1.13 Mn |
| Sep 30, 2025 | -1.13 Mn |
| Jun 30, 2025 | -5.77 Mn |
| Jun 30, 2025 | -5.77 Mn |
| Mar 31, 2025 | -2.83 Mn |
| Mar 31, 2025 | -2.83 Mn |
| Dec 31, 2024 | -2.41 Mn |
| Dec 31, 2024 | -2.41 Mn |
| Sep 30, 2024 | -5.46 Mn |
| Sep 30, 2024 | -5.46 Mn |
| Jun 30, 2024 | -4.56 Mn |
| Jun 30, 2024 | -4.56 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Mar 31, 2024 | 2.15 Mn |